NCOA5, IL-6, type 2 diabetes, and HCC: The deadly quartet

Debanjan Dhar; Ekihiro Seki; Michael Karin

doi:10.1016/j.cmet.2013.12.010

NCOA5, IL-6, type 2 diabetes, and HCC: The deadly quartet

Cell Metab. 2014 Jan 7;19(1):6-7. doi: 10.1016/j.cmet.2013.12.010.

Authors

Debanjan Dhar¹, Ekihiro Seki², Michael Karin³

Affiliations

¹ Laboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, University of California, San Diego, School of Medicine, 9500 Gilman Drive, San Diego, CA 92093, USA.
² Department of Medicine, University of California, San Diego, School of Medicine, 9500 Gilman Drive, San Diego, CA 92093, USA.
³ Laboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, University of California, San Diego, School of Medicine, 9500 Gilman Drive, San Diego, CA 92093, USA; Moores UCSD Cancer Center, University of California, San Diego, School of Medicine, 9500 Gilman Drive, San Diego, CA 92093, USA. Electronic address: [email protected].

Abstract

Although type 2 diabetes (T2D) is an established risk factor for hepatocellular carcinoma (HCC), the underlying mechanism that connects these two diseases is unknown. Gao et al. (2013) now suggest that nuclear receptor coactivator 5 (NCOA5) provides a genetic link between the two diseases through its effects on hepatic IL-6 expression.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Animals
Carcinoma, Hepatocellular / etiology*
Female
Glucose Intolerance / etiology*
Haploinsufficiency*
Humans
Liver Neoplasms / etiology*
Male
Nuclear Receptor Coactivators / genetics*

Substances

Nuclear Receptor Coactivators

Abstract

Publication types

MeSH terms

Substances

Grants and funding